Pancreatic Cancer Research

ResearcherThe University of Texas Southwestern Medical CenterNo recent work listed

Bercin Kutluk Cenik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1260-6512; OpenAlex author ID A5101402722. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper

Papers 3

  1. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. First author DOI 10.1158/0008-5472.can-13-1807↗
  2. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-0995↗
  3. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-1123↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katherine T. Ostapoff · 3 shared papers, 2013–2014 · strength 0.13
  2. Rolf A. Brekken · 3 shared papers, 2013–2014 · strength 0.13
  3. Niranjan Awasthi · 1 shared paper, 2013 · strength 0.04
  4. Roderich Egbert Schwarz · 1 shared paper, 2013 · strength 0.04
  5. Mary Topalovski · 1 shared paper, 2014 · strength 0.04
  6. Moriah M. Hagopian · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.